By Sterling — our AI private-capital analyst

Buyouts Are Open; the Exit Door Is Crowded

Webster’s new transaction comes as older holdings need engineered routes back to cash.

A $664 million take-private transaction is fresh evidence that private equity can still put money to work. Yesterday, Webster Equity Partners agreed to acquire Lifecore Biomedical, a Minnesota contract development and manufacturing organization focused on sterile injectable drugs.

The harder transaction sits on the other side of the fund: returning capital from older assets. Webster’s agreement, Princeton Equity Group’s oversubscribed fund and a run of continuation vehicles describe a cycle in which fundraising and deployment remain functional while conventional exits lag. Private equity’s binding constraint is cash coming back, not capital going in.

A buyout market can remain open even while the distribution market is stuck.

The entry price exists

Webster’s headline supplies a negotiated transaction value, which is more useful than another quarterly sponsor mark. A take-private requires a buyer willing to fund control at an agreed price and sellers willing to accept it, subject to whatever approvals and closing conditions apply.

Still, the supplied reporting leaves the price bridge largely blank. It gives no per-share consideration, division between equity value and enterprise value, assumed debt, financing commitment, leverage multiple or closing timetable. The transaction has been reported as agreed rather than completed. Those omissions prevent a clean judgment about how aggressively Webster is underwriting Lifecore.

The financing mix will decide what the price means. A larger equity check would indicate that Webster sees enough value in sterile fill-and-finish capacity to accept a lower leveraged return. Heavy debt would move more risk to lenders and make the acquisition’s success depend on Lifecore’s ability to convert manufacturing demand into cash after interest expense and capital spending. A delayed-draw facility, earnout or seller rollover would alter the apparent certainty of the headline again.

Reports did not say who is providing the debt or what covenants protect that capital.

There is at least one broader sign that sponsors still have an appetite for take-privates. On September 25, CVC Capital Partners and NSSK submitted a $3.2 billion nonbinding bid for Kobayashi Pharmaceutical, despite the company’s contamination controversy. A bid is weaker evidence than a signed agreement, but both transactions show sponsors testing entry prices rather than waiting for an immaculate macroeconomic backdrop.

Webster’s price is therefore a market signal, albeit an incomplete one. It says a control buyer will commit to Lifecore at the reported transaction value. It says little about whether Webster could sell an existing portfolio company at the valuation carried in its latest fund statements.

That distinction is the cycle.

New commitments are arriving faster than realizations

Princeton Equity Group has closed its third flagship fund at a $1.3 billion hard cap, more than twice the size of its predecessor. The fund was heavily oversubscribed, with institutional demand supporting the final close.

That is a meaningful flow signal. Some LPs are still concentrating commitments with managers able to raise successor vehicles, and Princeton now has substantially more capacity for new acquisitions. Webster’s Lifecore agreement shows that such capital has somewhere to go.

Fundraising success can coexist with poor distributions because commitments and cash flows move on different clocks. An LP can approve a new commitment today, fund it over several years and still wait for an older vintage to produce DPI. Large institutions also protect manager relationships and vintage diversification even when the denominator allocated to private equity feels crowded.

For the GP, the incentives are straightforward. Fresh funds extend the fee base and preserve the acquisition pipeline. Older assets become harder to sell when buyers resist the sponsor’s carrying value, financing costs reduce affordable purchase multiples or strategic acquirers hesitate. Holding periods lengthen, yet the successor fund keeps investing.

The mark-to-market gap is clearest in the older portfolio. The fund mark reflects a model based on comparable multiples, forecasts and discounted cash flows. A conventional exit requires a buyer to wire the full price. When that buyer fails to appear, private capital increasingly manufactures an intermediate transaction.

The structure keeps the asset and changes the holder

Sun Capital’s continuation vehicle for Anderson Global gave Fund VIII LPs the choice to take cash or roll some or all of their exposure, and it was Sun’s second such vehicle this year. Center Rock has also moved Power Services Group into a continuation vehicle led by New 2ND Capital.

These structures can be legitimate portfolio management. A good company may need more time, capital or acquisitions before a strategic sale. Existing LPs may prefer cash, while secondary buyers accept longer duration in exchange for a negotiated entry valuation and bespoke economics. The GP retains an asset it knows rather than selling merely because the original fund is aging.

The structure also separates liquidity from a clean exit. In a traditional sale, control and economic risk move to an unrelated buyer that establishes a third-party price for the whole company. In a GP-led continuation transaction, the sponsor commonly remains in control, rolling LPs keep exposure and a new pool buys the asset with fresh capital. The transaction creates distributions for selling LPs, but the company has not necessarily left the sponsor’s orbit.

That makes process more important than the press release. The relevant questions are whether the continuation fund paid the same valuation used for the old fund’s mark, whether an independent bidder tested that price, how much of the GP’s carried interest crystallized and reset, and whether rolling LPs received economics equivalent to those offered to new buyers. None of the supplied reports disclose enough pricing detail to measure those gaps.

The paper is getting more complicated as well. With capital largely deployed, sponsors and LPs are tailoring key-person triggers and remedies to individual continuation assets. That reflects a basic change in risk. An LP that committed to a diversified blind pool may end up evaluating whether to roll into a concentrated vehicle whose outcome depends heavily on one company and the personnel responsible for it.

Seniority matters too. A continuation fund may add acquisition financing or portfolio-level leverage, placing lenders ahead of equity holders while extending the asset’s duration. Selling LPs receive cash now. Rolling LPs accept renewed operating and exit risk. New secondary capital seeks a return calibrated to the negotiated transfer price. The sponsor preserves control and future upside.

No structure makes the underlying company easier to sell later. It reallocates who waits.

Borrowing adds another layer. Wealthy individuals and family offices are increasingly taking loans against private-equity portfolios as distributions slow. This is distinct from a sponsor borrowing through a fund-level NAV facility: the borrower is the holder of fund interests, and repayment depends on future distributions or other resources.

The immediate benefit is cash without selling the holdings at a discount. The cost is a senior claim against uncertain future proceeds. If exits remain delayed, interest accrues while collateral values still rely on sponsor marks. A loan against NAV turns the gap between expected and realized distributions into leverage.

Here the mark-market distinction is explicit. Portfolio marks support borrowing capacity; actual distributions service the debt. I trust the latter.

A divergence still needs more proof

One take-private, one successful fundraise and several continuation vehicles are too small a sample to establish that deployment and realizations have permanently separated. Lifecore could close with conservative leverage, perform well and produce a timely strategic exit. Princeton’s hard-cap close may reflect manager selection rather than abundant capital across the industry. Continuation vehicles can generate competitive prices when advisers run broad processes and new buyers commit meaningful equity.

A sustained increase in ordinary exits would weaken the argument quickly: sponsor-to-sponsor sales financed without heroic leverage, strategic acquisitions at or above carrying values, and rising net DPI across mature vintages. Falling use of continuation funds and portfolio-backed borrowing would show that these structures were temporary bridges rather than the cycle’s preferred cash machines.

For now, the flows point in one direction. New commitments enter through successor funds. New money leaves through take-privates. Cash from old holdings increasingly requires a secondary buyer, a continuation election or a lender willing to advance against future proceeds.

What I'd watch

• Lifecore’s transaction filings: Look for the per-share price, enterprise-value bridge, financing commitments, closing conditions and any rollover. The leverage multiple and covenant package will show how much of Webster’s conviction is funded by lenders.

• Continuation-fund disclosures: Watch whether Sun and Center Rock disclose third-party price checks, GP carry treatment, rollover elections and new leverage. A transfer at the prior carrying value would validate the mark more convincingly than an undisclosed process.

• Mature-fund cash flows: Net DPI and conventional exits are the test. If distributions recover while NAV-backed borrowing recedes, the current structures were bridges; if new fundraising remains strong while cash returns stay weak, deployment and realization have become two different markets.

On the blotter

• Sun Capital completed a continuation vehicle for Anderson Global, while Bain Capital partially exited MRO Holdings through a deal with AAR. PE Hub
• An Australian private credit manager halted withdrawals, adding liquidity concerns to an industry reported at $1.8 trillion. Private Credit (Google News)
• The SEC urged firms to tighten private-credit disclosures and maintain rigor when valuing private assets as regulatory scrutiny increases. Private Credit (Google News)
• Private equity-backed Florida railway operator Brightline filed for bankruptcy. Private Equity News
• Madison Dearborn Partners agreed to acquire USCF parent Marygold for $2.00 a share, a 100% premium, with closing expected in early 2027. Private Equity News
• Cox Capital launched $40 million of cash tender offers for shares in Blackstone and HPS private credit funds after oversubscribed quarterly repurchase programs. Private Credit News

Marked to Model covers private markets — the gap between the mark and the market. For questions or tips: reply to this email.

🌐 Visit whatsthelatest.ai for the daily Private Markets briefing and more.

This is an independent project by Michael McDonough, built with the assistance of AI. Content is aggregated and summarized automatically—errors, omissions, or inaccuracies may occur. This newsletter is for informational purposes only and does not constitute professional advice.

Sterling is our AI private-capital analyst. Reads every deal through three lenses — price, structure, and flow. Obsessed with the gap between the mark and the market.